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Literature Review/ 
Supporting Evidence 
• Erosion complications are infrequently reported <1% (C) 
• Probably unreported erosion (C) 
• Erosion develops overtime when the port septum is 
accessed at the same location each time(C)  
• Patients treated with Avastin were inversely proportional to 
erosions with the interval less than 14 days (C) 
• Port should be placed at depth of 0.5–2 cm (C,M) 
• Patients at risk: 
-Repetitive motions can cause skin to erode (C) 
-Significant amount of weight loss (C, M) 
-Possible correlation with the weight of the   
  breast pulling on skin above port site. (E) 
• Observation of lack of adequate securement of port access 
tubing to the patient causing skin damage at the access site. 
(E) 
• Regional telephone surveys of cancer centers indicate use 
of 20 Ga needles to access ports (E)  
• Premark bra strap line prior to insertion. (E) 
• Genetech Avastin recommendations  – Consider port 
placement  to be 14 days before or after Avastin 
administration (C). 
Percent of port erosions per year will be at or below the 
number reported in the literature. 
Level  Description  
A  Meta-analysis of multiple controlled studies or met synthesis of 
qualitative studies with results that consistently support a 
specific action, intervention,  
or treatment  
B  Well-designed controlled studies, both randomized and 
nonrandomized, with results that consistently support a specific 
action, intervention, or treatment  
C  Qualitative studies, descriptive or correlational studies, 
integrative reviews, systematic reviews, or randomized 
controlled trials with inconsistent results  
D  Peer-reviewed professional organizational standards, with 
clinical studies to support recommendations  
E  Theory-based evidence from expert opinion or multiple case 
reports  
M  Manufacturer’s recommendation only 
AACN Level of Evidence 
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Changes Implemented March 2011-September 2011 
• Change of Bard Power Port to version with lower profile 
palpation bumps 
• Change in access needle from 19 to 20 ga  
• Staff education on securing port access tubing and accurate 
documentation of port assessments 
• Staff education on providing patient teaching specific to 
caring for the access device (i.e. Using a pad to protect 
from bra straps or seat belts) 
• Radiology will mark bra straps prior to insertion  
• Radiologists have acknowledged the practice and support 
that  ports  should have depths of 0.5-2 cm 
• Continue to send eroded devices to Bard for review of 
medical device failure 
 
Changes Implemented  October 2011-December 2011 
• Medical Oncology will continue to consider timing of port 
placement  to be 14 days before or after Avastin 
administration 
• Change of Bard Power Port to upgraded version without 
profile palpation bumps 
• Mandatory education for nursing staff  at the Coborn 
Cancer Center and Radiology on new Bard Power Access 
needle and Tegaderm Securement Dressing   
• Change to Bard Power Access needle and Tegaderm 
Securement Dressing  in Outpatient Infusion at the Coborn 
Cancer Center 
 
January 2012 and Beyond 
• Mandatory education for nursing staff  at the St Cloud 
Hospital on new Bard Power Access needle and Tegaderm 
Securement Dressing   
• New Bard Power Access needle and Tegaderm Securement 
Dressing  for entire SCH implementation date expected 
April 2012 
Best Practice Changes Goal 
Team Members 
Outcomes 
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Port Erosion Complications•Technique Review 
•Change of access needle 
•Staff education on best practice changing 
•Marking of bra strap 
•Change of port access 
•Change of access needle  at Coborn Cancer Center 
•Change of securement device at Coborn Cancer Center 
•Mandatory education at Coborn Cancer Center 
 
 
Mandatory housewide education 
